REG - Physiomics PLC - Issue of Options

PhysiomicsAnnouncement

29/04/2022 10:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220429:nRSc8674Ja&default-theme=true

RNS Number : 8674J  Physiomics PLC  29 April 2022

29 April 2022

 

Physiomics plc

("Physiomics") or (the "Company")

 

Issue of Options

The Company considers that the award of options linked to the Company's
performance is critical to the incentivisation of its employees and to ensure
that there is alignment between management and shareholders.

To this end, the Company today confirms that it has agreed to issue 850,000
share options (the "Options") over ordinary shares of 0.4p each in the Company
("Ordinary Shares") to its non-director employees, under the Company's
existing Enterprise Management Initiative Employee Share Option Scheme (the
"Scheme") as detailed in this announcement.

Each Option issued will be exercisable at a price of 4.38p, being the greater
of (i) the average closing price for the three dealing days immediately
preceding the date of grant; and (ii) the closing price on the dealing day
immediately prior to the date of grant, as prescribed in the terms of the
Schemes.

The Options vest equally over a three-year period and can be exercised within
10 years of the date of grant.

Following this issue, there will be no change in the number of Options or in
the holdings of ordinary shares of directors in the Company.

The total number of shares in issue remains 97,424,778 Ordinary Shares with
voting rights attached (one vote per Ordinary Share). There are no Ordinary
Shares held in treasury. This total voting rights figure may be used by
shareholders as the denominator for the calculations by which they will
determine whether they are required to notify their interests in, or a change
to their interest in, Physiomics under the Disclosure and Transparency Rules.

 

 

Enquiries:

 

Physiomics
plc

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models
to support the development of cancer treatment regimens and personalised
medicine solutions. The Company's Virtual Tumour™ technology uses computer
modelling to predict the effects of cancer drugs and treatments to improve the
success rate of drug discovery and development projects while reducing time
and cost. The predictive capability of Physiomics' technologies have been
confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has
worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle
Therapeutics.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEILMPTMTATMTT